80 related articles for article (PubMed ID: 20488701)
1. Novel trivalent anti-influenza reagent.
Feng F; Miura N; Isoda N; Sakoda Y; Okamatsu M; Kida H; Nishimura S
Bioorg Med Chem Lett; 2010 Jun; 20(12):3772-6. PubMed ID: 20488701
[TBL] [Abstract][Full Text] [Related]
2. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy.
Matsubara T; Onishi A; Saito T; Shimada A; Inoue H; Taki T; Nagata K; Okahata Y; Sato T
J Med Chem; 2010 Jun; 53(11):4441-9. PubMed ID: 20476787
[TBL] [Abstract][Full Text] [Related]
3. Activity of isatine-sulfadimidine derivatives against 2009 pandemic H1N1 influenza virus in cell culture.
Selvam P; Chandramohan M; Hurst BL; Smee DF
Antivir Chem Chemother; 2010 Jan; 20(3):143-6. PubMed ID: 20054101
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 1-phenyl-cycloalkane carbamides as potent and selective influenza fusion inhibitors.
Tang G; Qiu Z; Lin X; Li W; Zhu L; Li S; Li H; Wang L; Chen L; Wu JZ; Yang W
Bioorg Med Chem Lett; 2010 Jun; 20(12):3507-10. PubMed ID: 20494579
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives.
Song JM; Park KD; Lee KH; Byun YH; Park JH; Kim SH; Kim JH; Seong BL
Antiviral Res; 2007 Nov; 76(2):178-85. PubMed ID: 17709148
[TBL] [Abstract][Full Text] [Related]
6. Glycotentacles: synthesis of cyclic glycopeptides, toward a tailored blocker of influenza virus hemagglutinin.
Ohta T; Miura N; Fujitani N; Nakajima F; Niikura K; Sadamoto R; Guo CT; Suzuki T; Suzuki Y; Monde K; Nishimura S
Angew Chem Int Ed Engl; 2003 Nov; 42(42):5186-9. PubMed ID: 14601167
[No Abstract] [Full Text] [Related]
7. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
[TBL] [Abstract][Full Text] [Related]
8. A monoclonal antibody specific to the HA2 glycoprotein of influenza A virus hemagglutinin that inhibits its fusion activity reduces replication of the virus.
Varecková E; Wharton SA; Mucha V; Gocník M; Kostolanský F
Acta Virol; 2003; 47(4):229-36. PubMed ID: 15068378
[TBL] [Abstract][Full Text] [Related]
9. Anti-influenza A virus activity of uridine derivatives of 2-deoxy sugars.
Krol E; Wandzik I; Gromadzka B; Nidzworski D; Rychlowska M; Matlacz M; Tyborowska J; Szewczyk B
Antiviral Res; 2013 Oct; 100(1):90-7. PubMed ID: 23911991
[TBL] [Abstract][Full Text] [Related]
10. Pomegranate (Punica granatum) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir.
Haidari M; Ali M; Ward Casscells S; Madjid M
Phytomedicine; 2009 Dec; 16(12):1127-36. PubMed ID: 19586764
[TBL] [Abstract][Full Text] [Related]
11. Rational design of potent sialidase-based inhibitors of influenza virus replication.
von Itzstein M; Wu WY; Kok GB; Pegg MS; Dyason JC; Jin B; Van Phan T; Smythe ML; White HF; Oliver SW
Nature; 1993 Jun; 363(6428):418-23. PubMed ID: 8502295
[TBL] [Abstract][Full Text] [Related]
12. Activity of Melaleuca alternifolia (tea tree) oil on Influenza virus A/PR/8: study on the mechanism of action.
Garozzo A; Timpanaro R; Stivala A; Bisignano G; Castro A
Antiviral Res; 2011 Jan; 89(1):83-8. PubMed ID: 21095205
[TBL] [Abstract][Full Text] [Related]
13. Free energy simulations reveal a double mutant avian H5N1 virus hemagglutinin with altered receptor binding specificity.
Das P; Li J; Royyuru AK; Zhou R
J Comput Chem; 2009 Aug; 30(11):1654-63. PubMed ID: 19399777
[TBL] [Abstract][Full Text] [Related]
14. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
Baranovich T; Saito R; Suzuki Y; Zaraket H; Dapat C; Caperig-Dapat I; Oguma T; Shabana II; Saito T; Suzuki H;
J Clin Virol; 2010 Jan; 47(1):23-8. PubMed ID: 19962344
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.
Ilyushina NA; Bovin NV; Webster RG; Govorkova EA
Antiviral Res; 2006 Jul; 70(3):121-31. PubMed ID: 16516984
[TBL] [Abstract][Full Text] [Related]
16. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance.
Ehrhardt C; Hrincius ER; Korte V; Mazur I; Droebner K; Poetter A; Dreschers S; Schmolke M; Planz O; Ludwig S
Antiviral Res; 2007 Oct; 76(1):38-47. PubMed ID: 17572513
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel L-ascorbic acid-conjugated pentacyclic triterpene derivatives as potential influenza virus entry inhibitors.
Wang H; Xu R; Shi Y; Si L; Jiao P; Fan Z; Han X; Wu X; Zhou X; Yu F; Zhang Y; Zhang L; Zhang L; Zhou D; Xiao S
Eur J Med Chem; 2016 Mar; 110():376-88. PubMed ID: 26866456
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibitory effect of carrageenan oligosaccharide on influenza A H1N1 virus.
Wang W; Zhang P; Hao C; Zhang XE; Cui ZQ; Guan HS
Antiviral Res; 2011 Nov; 92(2):237-46. PubMed ID: 21867732
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.
Conti G; Magliani W; Conti S; Nencioni L; Sgarbanti R; Palamara AT; Polonelli L
Antimicrob Agents Chemother; 2008 Dec; 52(12):4331-7. PubMed ID: 18824612
[TBL] [Abstract][Full Text] [Related]
20. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
Gubareva LV; Kaiser L; Matrosovich MN; Soo-Hoo Y; Hayden FG
J Infect Dis; 2001 Feb; 183(4):523-31. PubMed ID: 11170976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
